Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche ...

The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene ...

After discontinuing development of its lead asset, Fulcrum Therapeutics has provided more details on its restructure, with 48 of 57 employees headed out the door. Fulcrum Therapeutics’ restructure ...

Otsuka Pharmaceuticals’ APRIL inhibitor Voyxact stabilized kidney function decline in a late-stage IgA nephropathy study—findings analysts say could have broader implications across the drug class, ...

The FDA hasn’t been transparent and open enough with how it has implemented the Commissioner’s National Priority Voucher program, patient, industry and trade groups said Thursday. Several ...

Pfizer scientists will leverage Chai Discovery’s AI platform - including Chai-3, its most advanced model - alongside custom software, to help accelerate drug discovery research SAN ...

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to ...

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

Alnylam Pharmaceuticals is linking up with Inceptive Nucleics in a deal that aligns with the growing biopharma trend of using generative AI to aid drug development. The Massachusetts biotech is ...

With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs. Eli Lilly and ...

Parabilis Medicines is joining the parade of biotechs going public, sharing plans to raise as much as $476.4 million to help advance its lead cancer candidate into late-stage testing. Shortly after ...